In India, COPD affects over 37 million people and is one of the main causes of death in the country.
With the introduction of Vilfuro-G, the first fixed-dose triple combination medication globally for the efficient treatment of chronic obstructive pulmonary disease (COPD) in India, pharmaceutical company Lupin announced on Thursday that it was broadening its range of respiratory products.
This comes after the Dry Powder Inhaler (DPI) product received approval from the Drug Controller General of India.
The only FDC that combines glycopyrronium bromide, fluticasone furoate, and vilanterol is called Vilfuro-G by Lupin, and it is intended for the long-term treatment and management of moderate to severe COPD.
With COPD becoming more and more common worldwide, India is responsible for a substantial 18% of the disease’s burden. We take great pride in providing patients and medical professionals with cutting-edge treatment options thanks to our broad respiratory portfolio and Vilfuro-G approval, said Rajeev Sibal, President, India Region Formulations, Lupin.
It is advised to use the product, which comes in a fixed dose of one strength, once daily. In India, COPD affects more than 37 million people and is one of the main causes of death and disability in the country.
According to Nilesh Gupta, Managing Director of Lupin, “this innovative milestone reinforces our resolve to expanding our respiratory portfolio, giving COPD patients access to healthcare solutions, and transforming lives.”